Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.

NCT00348309 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00348309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00348309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 54-week, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Effects of Rosiglitazone (Extended Release Tablets) as Adjunctive Therapy to Donepezil on Cognition and Overall Clinical Response in APOE ε4-stratified Subjects With Mild to Moderate Alzheimer's Disease.
Lead sponsor
GlaxoSmithKline
Phase
Not applicable
Overall status
Completed
Start date
July 6, 2006
Completion date
January 28, 2009
Enrollment
1,496 (actual)
Sites
249

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease